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In order to explore how health-related quality of life changes towards the end of life, a questionnaire including the EuroQOl form and
the Brief Pain Inventory form was sent to all men with prostate cancer in the county of O ¨ stergo ¨tland, Sweden, in September 1999.
Responders who had died prior to 1 January 2001 were later identified retrospectively. Of the 1442 men who received the
questionnaire, 1243 responded (86.2%). In the group of responders, 167 had died within the study period, 66 of prostate cancer. In
multivariate analysis, pain as well as death within the period of study were found to predict decreased quality of life significantly. Of
those who died of prostate cancer, 29.0% had rated their worst pain the previous week as severe. The same figure for those still alive
was 10.5%. On a visual analogue scale (range 0–100), the mean rating of quality of life for those who subsequently died of prostate
cancer was 54.0 (95% confidence interval 75.2) and those still alive was 70.0 (71.2). In conclusion, health-related quality of life
gradually declines during the last year of life in men with prostate cancer. This decline may partly be avoided by an optimised pain
management.
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In recent years, health-related quality of life has become one of the
most important end points for studies on men with prostate
cancer, especially men with cancer at an advanced stage. Caring for
cancer patients in the last years of life requires a good
understanding of how health-related quality of life can be
improved when efforts to prolong life become increasingly futile.
Adequate pain and symptom management, avoidance of inap-
propriate prolongation of the dying process, achievement of a
sense of control, relief of burdens, and the strengthening of
relations with loved ones have been found to be the most
important domains from the patient’s perspective of palliative
treatment (Singer et al, 1999). Of all factors affecting health-related
quality of life, however, pain is usually considered the most
prominent factor for patients approaching death (Elliott, 1997).
Although pain management is fundamental in terminal care
(Steinhauser et al, 2000; Wrede-Seaman, 2001), it is often
undertreated (Perron and Schonwetter, 2001). According to the
World Health Organisation’s guidelines for the stepwise manage-
ment of pain in cancer, the potency of the analgesia provided,
ranging from non-opioids and opioids for moderate pain (e.g.
dextropropoxyphene, codeine and tramadol) to opioids for severe
pain (e.g. morphine, cetobemidone and fentanyl), should be
adjusted to the patient’s experienced level of pain (WHO, 1986). If
this is implemented consistently and proper palliative approaches
are maximised, it has been claimed that effective pain control may
be achieved in 80% of cancer patients (Perron and Schonwetter,
2001). However, despite the widespread acceptance of this strategy,
more than 40% of prostate cancer patients in routine practice
settings report the presence of pain (Greenwald et al, 1987;
Portenoy, 1989; Larue et al, 1995; Sandblom et al, 2001).
Health-related quality of life in the final year of life in terminally
ill patients, including men with prostate cancer, has been studied
previously (Liao et al, 2000; Litwin et al, 2001; Melmed et al, 2002).
However, in order to reach a full understanding of how health-
related quality of life is affected by approaching death, all patients
in a population-based sample must be studied. We have therefore
analysed the outcome of a questionnaire that was sent to all men
with prostate cancer in the county of O ¨stergo ¨tland, Sweden, in
1999. The questionnaire consisted of EuroQol, designed to evaluate
health-related quality of life, and Brief Pain Inventory Form (BPI),
which consists of questions with regard to the severity and impact
of pain on daily functions. The results from this study have been
published previously (Sandblom et al, 2001). We now present a
separate analysis of men in the same cohort who died before 1
January 2001, who were identified by crosslinking with the
National Death Register.
MATERIAL AND METHODS
Study base
The basic source of information was a questionnaire sent to all
men with prostate cancer in the county of O ¨stergo ¨tland. O ¨stergo ¨t-
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lland is one of three counties of the South-East Health Care Region
of Sweden (O ¨stergo ¨tland, Jo ¨nko ¨ping and Kalmar county). The total
population in O ¨stergo ¨tland in 1999 was 412000. It has two
peripheral hospitals and one central referral hospital. All cases of
prostate cancer were identified in the National Tumour Register,
which was started in 1958 as a population-based cancer register
and has a coverage greater than 98% (Mattsson, 1977). It contains
data on all tumours diagnosed, including personal number and
date of diagnosis. For cases diagnosed in 1987 or later additional
data on tumour stage, grade and treatment were extracted from the
South-East Region Prostate Cancer Register, which serves as an
extension of the National Tumour Register (Sandblom et al, 2000).
The register has been validated and shown to have a high
reproducibility (Sandblom et al, 2003). For cases diagnosed prior
to 1987, data were achieved through a review of case histories at
each respective urology department. The central death register was
searched for cases who had died before the start of the study
period and these were excluded. All data from the questionnaire
were converted into electronic form by scanning and then checked
once manually.
In 2003, the central death register was checked for men included
in the study who had died within 1 year of the day the
questionnaire was distributed. In this study, we primarily used
the cause of death recorded in the South-East Region Prostate
Cancer Register. When cause of death was not registered in the
South-East Region Prostate Cancer Register, we relied on the cause
of death registered in the central death register.
Subjects
There were 7199 cases of prostate cancer diagnosed in O ¨stergo ¨t-
land registered in the National Tumour Register up to 31
December 1998; of these 4474 were registered as dead in the
Tumour Register. In all, 30 cases were excluded due to incomplete
personal registration number, diagnosis before 1969, or because
they were born before 1900. The remaining 2695 were crosslinked
with the National Population Register, which resulted in the
further exclusion of 1145 deceased men, eight men, where
matching with the personal registration number was impossible
to achieve, and 40 men who had left the county. In a repeat match
with the population register in November 1999, an additional 60
deaths were discovered, leaving 1442 cases in the group studied.
The first letter with the questionnaire and an explanation was
sent in September 1999. Two further letters were sent 2 and 4
weeks after the first letter as reminders to nonresponders. A nurse
was available on the telephone at each of the three urology
departments in the county for general information and clarifica-
tion of the questions.
Questionnaire
The questionnaire was a combination of the EuroQol, parts of the
BPI and eight specially designed questions. Altogether, there were
26 questions.
EuroQol is a nondisease-specific instrument for describing and
evaluating health-related quality of life (EuroQolr Group, 1990).
It was developed as an internationally standardised complement to
other health status measures, having five questions covering the
basic domains common to generic health status and a visual
analogue scale (VAS) for the indication of general health state. The
answers to the first five questions can be derived to produce an
overall index of health status (EQ-5D). A validation of EuroQol in
Sweden has shown a striking similarity to results from other
European centres (Brooks et al, 1991).
The BPI is an instrument designed to assess the severity of pain
and impact of pain on daily functions among patients with cancer
pain and pain due to chronic disease. It rates the degree to which
pain interferes with mood, walking and other physical activities,
work, social activity, relationships with others and sleep. The BPI
has been validated in several studies (Serlin et al, 1995; Cleeland
et al, 1996). In our study, we included the four BPI questions
related to pain intensity (pain now, worst pain last weak, least pain
last weak and average pain last week) and the seven questions
related to pain interference with daily functions (interference with
general activity, mood, walking, work, relations with others, sleep
and enjoyment of life).
In addition to the standardised questions from EuroQOL and
BPI, eight specially designed questions inquiring about the
effectiveness of pain treatment, whether pain treatment was given
in time, side effects of treatment, which medications had been
prescribed, civil state and how easy it was to get in contact with a
nurse or doctor when needed were also included.
Pain management index
To determine whether the patient was adequately managed for his
pain, a pain management index (PMI) was determined (Cleeland
et al, 1994). The index was derived by subtracting the rating of
worst pain on the BPI questionnaire from a score corresponding to
the strongest prescribed analgesic as reported by the respondent.
The analgesic drug score was defined according to the WHO’s
analgesic ladder: 0 for no analgesic, 1 for nonopioids, 2 for opioids
for moderate pain, and 3 for opioids for severe pain. Based on the
worst pain as stated in the BPI questionnaire, the pain score (0–
10) was categorised as 0 for no pain (rating 0), 1 for mild pain
(rating 1–3), 2 for moderate pain (rating 4–7) and 3 for severe
pain (rating 8–10). A negative score indicates undertreatment of
the pain (Cleeland et al, 1994). Although PMI is not accurate for
prescribing drug to an individual, it provides a rough estimate of
how pain is treated in the population.
Statistics
In the analyses, localised tumours were defined as T0-2, NX/N0
and M0, and all others were treated as advanced. The treatment
was categorised into three groups: watchful waiting; palliative
treatment (including bilateral orchiectomy, GnRH-analogues,
transurethral resection of the prostate, antiandrogens and oestro-
gen); and treatment with curative intent (including radical
prostatectomy, external radiation therapy and brachytherapy). In
a multivariate regression analysis, factors predicting outcome from
the BPI question with regard to ‘worst pain the last week’ (11
grades) were assessed, including patient age, civil state, time since
diagnosis, presence of distant metastases at time of diagnosis, last
received treatment, rating of health-care availability and death
within 1 year of questionnaire distribution as independent
variables. Treatment was divided into palliative, curative and
watchful waiting, with watchful waiting considered as reference.
The rating of health care availability was divided into three
categories: ‘no need of contact’; ‘easy to get in contact’ (always easy
or usually easy to get in contact); and ‘difficult to get in contact’
(neither easy nor difficult, usually difficult and always difficult).
‘No need for contact’ and ‘difficult to get in contact’ were included
in the analysis and ‘easy to get in contact’ was treated as reference.
Death within 1 year of distribution of the questionnaire was
divided between death from prostate cancer and death from other
causes.
Similarly, factors predicting health-related quality of life as
stated on the VAS in the EuroQol questionnaire were assessed in a
multivariate regression analysis, with age, civil state, time since
diagnosis, tumour stage (localised/advanced), last received treat-
ment, the rating of ‘pain on average the last week’, rating of health-
care availability and death within 1 year of questionnaire
distribution, as independent variables. A multivariate logistic
regression analysis with age, treatment, civil state, presence of
distant metastases at diagnosis, time since diagnosis, rating of
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distribution was used to assess risk factors for negative PMI.
RESULTS
Of the 1442 who received the questionnaire, 1243 (86%) responded
(Table 1). The reasons for drop out were: absence of response
(n¼145); inability to answer due to disease (n¼34); absence of
answers in the returned questionnaires (n¼8); refusal to answer
(n¼5); not reachable at noted address (n¼4); change of address
(n¼1); answered by wrong person (n¼1); and too incoherent
answers to allow adequate interpretation (n¼1). Of the 1243
responders, 78 had prostate cancer diagnosed before 1987.
In the group of responders, 167 (13.4%) died before 1
January2001, 66 (5.3%) of prostate cancer and 100 (8.0%) of other
causes. Cause of death could not be identified for one patient. Of
the 199 nonresponders, 70 (35.2%) had died before 1 January 2001,
20 (10.1%) of prostate cancer. From now, all analyses refer to the
1243 responders.
The primary treatment of the 1243 responders was distributed
between watchful waiting (n¼582), palliative treatment, including
bilateral orchiectomy (n¼127), GnRH analogues (n¼238),
transurethral resection of the prostate (TUR-p, n¼37), antiandro-
gens (n¼15), oestrogen (n¼8), and treatment with curative
intent, including radical prostatectomy (n¼156), external radia-
tion therapy (n¼58) and brachytherapy (n¼16). Information on
treatment was missing for six cases. Of those initially managed
with watchful waiting, 15 later received treatment with curative
intent and 184 received palliative treatment. Similarly, of those
who initially were treated with curative intent, 30 patients later
received palliative treatment, and of those initially receiving
palliative treatment four were later treated with curative intent.
At the time of the questionnaire, 383 men were thus managed with
watchful waiting, 635 received palliative treatment and for 219
treatment with curative intent was registered as the last treatment
received.
In multivariate regression analyses, death before 1 January 2001
was found to be a significant factor predicting the rating of ‘Worst
pain last week’ in the BPI as well as health-related quality of life as
estimated by the VAS in the BPI (Tables 2–3, Figures 1–3). For
PMI, however, death during the period of study was not found to
be a significant predictive factor in a multivariate logistic analysis
(Table 4).
Men who died of prostate cancer were found to report ‘worst
pain last week’ significantly higher than men who died of other
causes when testing with Mann–Whitney U-test (Po0.05). There
were only minor nonsignificant differences in health-related
quality of life between those who died of prostate cancer and
those who died of other causes (Table 1).
For all BPI questions with regard to interference of pain with
daily functions, a significant difference in the ratings were seen
between those who died within the study period and those still
alive (all Po0.005). Except for interference with work (Po0.05),
no significant difference was seen between those who died of
Table 1 Distribution of age, ratings of quality of life and number of patients taking strong opioids for patients who died of prostate cancer, patients who
died of other causes and patients still alive (n¼1242, cause of death not registered for one patient)
Died of prostate cancer Died of other causes Still alive 31 December 2000
Number 66 100 1076
Age (years, 7s.d.) 76710 82767 7 78
Eq5D score (795% confidence interval) 0.53870.077 0.56470.067 0.77070.015
EuroQOL VAS (795% confidence interval) 54.075.2 53.274.6 70.071.2
Number of patients receiving strong opioids 17 (25.8%) 3 (3.0%) 15 (1.4%)
VAS¼visual analogue scale.
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Figure 1 Quality of life, as rated on the EuroQol VAS, during the last 16
months of life. 7 95% confidence interval.
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Figure 2 Quality of life, as estimated by the EQ-5D score, during the last
16 months of life. 7 95% confidence interval.
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Figure 3 Distribution of ratings of ‘worst pain last week’ in BPI (number
of responders within parenthesis).
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pain interference questions (Figure 4A–G)
DISCUSSION
The present study represents the outcome of a geographically
defined cohort of men with prostate cancer in their final year of
life. The population-based design helps to avoid bias due to
selection of patients managed at specialised units and other
selection processes associated with the disease or general health
status of the patient. Several of the previously published studies of
health-related quality of life in the final years of life are based on
patients treated at referral centres, which inevitably results in a
convenience sample. A minor source of bias in the present study
are the nonresponders, who were over-represented among those
who died within 1 year of questionnaire distribution. In this group,
there may be a number of patients who were unable to answer the
questionnaire since they had reached the terminal stage of their
disease.
Of those who died of prostate cancer, 27.6% stated their ‘worst
pain last week’ as severe. Whether this should be considered
acceptable and reflecting optimal pain treatment is an open
question. With the updated interpretation of the WHO analgesic
ladder (Coluzzi, 1998), which advocates earlier introduction of
opioids, unnecessary suffering from chronic malignant pain may
in many cases be avoided. It has been claimed that it is possible to
achieve good pain relief in 90–95% of dying patients (Elliott, 1997;
Harrold, 1998). However, the reasons for pain in men with
advanced prostate cancer are often complex and may need
approaches other than opioid treatment. Many of these patients
probably suffer not only from nociceptive pain but also from
neuropathic pain due to metastases compressing nerve rotes. This
type of pain is not completely opioid responsive (Arner and
Meyerson, 1988; Cherny and Portenoy, 1994) and may require
surgical neurectomy or anaesthetic block techniques. Patients with
metastases to the retroperitoneal lymph nodes or the liver may also
experience visceral pain. Intolerance to opioid treatment is a
further problem that should not be ignored. If side effects of the
treatment, such as constipation and nausea, are not managed
carefully, the reduction of health-related quality caused by the
disease itself may be even further pronounced. Despite the
effectiveness of opioids for treatment of nociceptive pain, complete
pain relief is not always achievable. The complex nature of cancer
pain makes it unlikely to reach a complete pain relief for more
than 90% of these patients, even under optimised circumstances
(Serlin et al, 1995; Zech et al, 1995).
In the case of widespread skeletal metastases, radiotherapy
directed against painful bone metastases or intravenous
treatment with radionuclides relieves pain effectively. Bispho-
sphonates or corticosteroids may also be used as adjuvant pain
treatment to men with painful bone metastases. In addition to
pharmacological pain treatment, there are a number of
alternative nonpharmaceutical approaches that have not been
fully evaluated, such as transcutaneous electrical nerve stimula-
tion, acupuncture or massage therapy. Although the mecha-
nisms for these types of treatment are poorly understood,
they can be attempted as a complement to pharmacological
treatment.
Since no palliative therapy other than hormonal treatment has
been consistently recorded in the South-East Region Prostate
Cancer Register, we do not know how patients with hormone-
refractory prostate cancer have been treated. Radiotherapy and
radionuclide treatment are established as standard in the South-
East Region for treating men with painful metastases and has
probably been given to the majority of these patients. All other
treatments have been provided on individualised terms.
Despite the absence of a significant association between death
within the period of study and negative PMI, there may still be a
Table 2 Variables predicting ‘worst pain last week’ in a multivariate
regression analysis
t-value Significance
Health-care availability 5.32 o0.001
Dead before 31 December 2000 3.90 o0.001
Time since diagnosis 1.88 0.061
Treatment with curative intent  1.66 0.097
Civil state 1.29 0.20
Palliative treatment 1.11 0.27
Age (years)  0.36 0.72
Presence of distant metastases at diagnosis 0.08 0.94
Table 3 Factors predicting health-related quality of life as estimated on
the EuroQol VAS in a multivariate regression analysis
t-value Significance
Worst pain last week  15.47 o0.001
Dead before 31 December 2000  5.91 o0.001
Age (years)  5.84 o0.001
Health-care availability  4.90 o0.001
Palliative treatment  2.26 0.024
Time since diagnosis  0.71 0.48
Tumour stage at diagnosis 0.50 0.62
Civil stage 0.26 0.80
Treatment with curative intent  0.043 0.97
VAS¼visual analogue scale.
Table 4 Factors predicting a negative pain management index in a
multivariate logistic analysis
Factor Estimated odds ratio Significance
Health-care availability 0.69 o0.001
Distant metastases at diagnosis 2.89 0.001
Treatment with curative intent 0.66 0.053
Dead before 31 December 2000 1.13 0.538
Civil state 1.10 0.560
Time since diagnosis 1.00 0.576
Palliative treatment 0.98 0.914
Age (years) 1.00 0.992
Figure 4 (A) Distribution of answers to the BPI question of how pain interferes with general activities (number of responders within parenthesis). (B)
Distribution of answers to the BPI question of how pain interferes with mood (number of responders in brackets). (C) Distribution of answers to the BPI
question of how pain interferes with walking (number of responders within parenthesis). (D) Distribution of answers to the BPI question of how pain
interferes with work (number of responders within parenthesis). (E) Distribution of answers to the BPI question of how pain interferes with relations with
other people (number of responders within parenthesis). (F) Distribution of answers to the BPI question of how pain interferes with sleep (number of
responders within parenthesis). (G) Distribution of answers to the BPI question of how pain interferes with enjoyment of life (number of responders within
parenthesis).
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lnumber of undertreated patients. Difficulties in getting into
contact with the health-care facilities, dissimulation or inappropri-
ate reluctance to take strong opioids for fear of addiction or side
effects may result in patients not receiving the treatment they
require. By constructing a model based on the same cohort as in
the present study, it was shown that 0.82 quality-adjusted life-years
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lcould theoretically be added to every man in the cohort if pain
treatment is optimised (Sennfa ¨lt et al, 2003).
Since we do not know how many of the men were still working
when they answered the questionnaire, it is difficult to interpret
the question with regard to the impact of pain on work. There were
98 men (7.9%) who were 65 years or younger, which is the age
when you are retired in Sweden if you do not receive early
retirement pension. However, it is difficult to give any other
explanation for the difference between men who died of prostate
cancer and those who died of other causes probably than that men
in the first group were more disabled by their disease (Figure 4D).
A decrease in health-related quality of life was seen during the
final year of life, especially during the final 4 months (Figure 2).
Designing a questionnaire that reflects all the physical, psycholo-
gical, social and spiritual changes that take place towards the end
of life, each interfering with all the others, would be extremely
difficult. However, the VAS as well as the EuroQol index give a
good overall depiction of how health-related quality of life is
affected. Only the patient himself can truly define his own quality
of life, which is the strength of the VAS.
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